1. 21 CFR 320.1(c) Code of Federal Regulations; Title 21, Food and drugs; Part 320, Bioavailability and bioequivalence requirements.
2. Lee S, Raw A, Yu L, Lionberger R, Ya N, Verthelyi D, Rosenberg A, Kozlowski S, Webber K, Woodcock J. Scientific considerations in the review and approval of generic enoxaparin in the United States. Nat Biotechnol. 2013;31(3):220–6.
3. US Food and Drug Administration. FDA approves first generic enoxaparin sodium injection. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm220092.htm (2017). Accessed 2 Jan 2017.
4. US Food and Drug Administration. Response to Citizen Petition, Docket No. FDA-2003-P-0273. http://www.regulations.gov (2010).
5. US Food and Drug Administration. FDA approves first generic Copaxone to treat multiple sclerosis. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm443143.htm (2017). Accessed Jan 2 2017.